Literature DB >> 11445126

Myasthenia gravis.

A Vincent1, J Palace, D Hilton-Jones.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11445126     DOI： 10.1016/S0140-6736(00)05186-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  112 in total

1.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

3.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

4.  Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia.

Authors:  Claire Vandiedonck; Geneviève Beaurain; Matthieu Giraud; Catherine Hue-Beauvais; Bruno Eymard; Christine Tranchant; Philippe Gajdos; Jean Dausset; Henri-Jean Garchon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

5.  An adult patient with new-onset dysphagia.

Authors:  Kieran McIntyre; Simon McVaugh-Smock; Ophyr Mourad
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

6.  Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.

Authors:  Rumi Sato; Shiho Imamoto; Iku Utsnomiya; Terumasa Chiba; Kyoji Taguchi; Kenji Abe; Keiko Tanaka; Tadashi Miyatake
Journal:  Neurol Sci       Date:  2013-02-07       Impact factor: 3.307

Review 7.  Neuromuscular disorders and sleep.

Authors:  Ibrahim Oztura; Christian Guilleminault
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

8.  Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.

Authors:  Douglas B Johnson; Vita Saranga-Perry; Patrick J M Lavin; W Bryan Burnette; Stephen W Clark; David R Uskavitch; Deborah E Wallace; Mark A Dickson; Ragini R Kudchadkar; Jeffrey A Sosman
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

10.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.